BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16920505)

  • 1. Principles of dendritic cell-based immunotherapy in myeloid leukemia.
    Westers TM; Houtenbos I; van de Loosdrecht AA; Ossenkoppele GJ
    Immunobiology; 2006; 211(6-8):663-76. PubMed ID: 16920505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
    Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Biomed Pharmacother; 2007 Jul; 61(6):306-14. PubMed ID: 17368821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
    van den Ancker W; van Luijn MM; Westers TM; Bontkes HJ; Ruben JM; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Immunotherapy; 2010 Jan; 2(1):69-83. PubMed ID: 20635890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.
    Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Itoh T; Shimizu A; Kuzushima K; Kondo T; Ishikawa T; Uchiyama T
    Exp Hematol; 2011 Apr; 39(4):424-433.e2. PubMed ID: 21216276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can leukemia-derived dendritic cells generate antileukemia immunity?
    Rosenblatt J; Avigan D
    Expert Rev Vaccines; 2006 Aug; 5(4):467-72. PubMed ID: 16989627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells.
    Tong XM; Yao HP; Qian WB; Zhu LF; Fu ZH; Huang ZL; Jin J
    Int J Lab Hematol; 2008 Oct; 30(5):372-81. PubMed ID: 18205840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
    Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
    Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2006 Mar; 91(3):348-55. PubMed ID: 16531258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell vaccines for leukemia patients.
    Schmitt A; Hus I; Schmitt M
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):275-83. PubMed ID: 17338648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
    Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
    Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies in immunotherapy for acute myeloid leukemia.
    Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
    Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapy: achievements and perspectives.
    Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.